ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion

Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting https://www.prnewswire.com/news-releases/accuray-and-c-rad-unveil-automated-breast-cancer-treatment-package-for-the-radixact-system-at-american-society-for-radiation-oncology-astro-annual-meeting-301648231.html ...will showcase an important new option for improving the care of people diagnosed with breast cancer during the 2022 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Antonio, Texas, October 23 – 26, 2022.

https://investors.accuray.com/news-releases/news-release-details/accuray-and-c-rad-unveil-automated-breast-cancer-treatment

In The Lancet Oncology veröffentlichte Daten weisen darauf hin, dass bei Männern mit Prostatakrebs, die mit der Accuray CyberKnife(R)-Plattform behandelt wurden, weniger Blasennebenwirkungen auftraten als bei Männern, die mit herkömmlichen Linearbeschleunigern behandelt wurden https://www.stocktitan.net/news/ARAY/data-published-in-the-lancet-oncology-indicate-men-with-prostate-sab8ayvqf5zx.html

Accuray kündigt erste CyberKnife ® -Systeme in Afrika an, die eine neue Option und Hoffnung auf potenziell lebensrettende Strahlenbehandlungen für mehr Krebspatienten bieten

Ich bin auch nicht unzufrieden, aber Geduld wird man trotzdem noch brauchen. So ziehe ich sie nebenbei per Sparplan höher und den Rest macht das Unternehmen 😉

Ich finde das man genug Informationen erhält und es stimmen auch die Zahlen. Ein gutes Unternehmen für die Zukunft

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00517-4/fulltext

Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster https://www.prnewswire.com/news-releases/accuray-partners-with-swiss-based-genolier-innovation-hub-to-bring-medical-and-technological-advances-to-patients-faster-301618994.html

Na sie lebt noch

Accuray rises 5% following fiscal 2022 Q4 beats, fY 2023 revenue range within consensus https://seekingalpha.com/news/3871144-accuray-rises-5-following-fiscal-2022-q4-beats-fy-2023-revenue-range-within-consensus • Accuray Inc. (NASDAQ:ARAY) is up 5% in after-hours trading after reporting fiscal 2022 Q4 results that beat on the top and bottom lines and issuing a FY 2023 revenue estimate that falls within analyst consensus. • The company projects FY 2023 revenue of $447M-$455M. The consensus estimate is $451.29M • Adjusted EBITDA is expected in the range of $26 million to $30 million. • Net loss of ~3.5M in the quarter was ~69% narrower compared to FQ4 2021. • Revenue of $110.M was a ~1% year-over-year increase. • Accuray ended the quarter with $88.7M in cash and cash equivalents, a 24% decline from the end of FQ4 2021.

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M https://seekingalpha.com/news/3870996-accuray-gaap-eps-of-0_04-beats-0_03-revenue-of-110_02m-beats-4_7m

Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2022-financial-results-301603116.html 8.5% FY22 revenue growth; Company issues guidance for FY23

https://www.surgicalroboticstechnology.com/news/new-clinical-studies-show-benefits-of-accuray-cyberknife-in-treatment-of-neurological-indications/

Sau 👍

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological https://www.prnewswire.com/news-releases/accuray-cyberknife-system-real-world-data-and-clinical-studies-show-benefits-in-treatment-of-neurological-indications-301583528.html

https://www.benzinga.com/quote/ARAY/analyst-ratings Accuray Price Target Announced at $7.50/Share by B. Riley Securities